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Abstract 
Clinical practice guidelines (CPGs) are used to support clinicians and patients in diagnostic and 
treatment decision-making.  Along with patients’ preferences and values, and clinicians’ 
experience and judgment, practice guidelines are a critical component to ensure patients are 
getting the best care based on the most updated research findings.  Most CPGs are based on 
systematic reviews of the treatment literature.  Although most reviews are now restricted to 
randomized controlled trials, others may consider non-randomized effectiveness trials. Despite a 
reliance on similar procedures and data, methodological decisions and the interpretation of the 
evidence by the guideline development panel can result in different recommendations.  In this 
paper we will describe key methodological points for five recently released CPGs on the 
treatment of PTSD in adults and highlight some of the differences in both the process and 
subsequent recommendations. 
Clinical Impact Statement: 
Question: What are the primary posttraumatic stress disorder treatment recommendations across 
the various PTSD clinical practice guidelines? 
Findings: All of the guidelines gave the highest overall recommendations to trauma-focused 
psychotherapies (usually including Eye Movement Desensitization and Reprocessing) and all 
agreed that Selective Serotonin Reuptake Inhibitors (either specific ones or the whole class) were 
the most effective medications.   
Meaning: There is general consistency across the PTSD clinical practice guidelines. 
Next Steps: Clinical practice guideline recommendations need to be disseminated to clinicians 
and, along with patient preferences, used to guide treatment decision-making. 
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A Guide to Guidelines for the Treatment of Posttraumatic Stress Disorder in 
Adults: An Update 
Choice is an integral component in the process of treating physical and mental health 
conditions—first, about whether any treatment will be pursued, and second, the nature of the 
treatment(s) that will be used.  In the optimal scenario, the decision is informed by scientific 
evidence, a clinician’s experience and training, and a patient’s preferences and values. These 
three elements meet the definition of an evidence-based practice provided by the Presidential 
Task Force on Evidence-Based Practice (American Psychological Association; APA, 2006).   
Clinical practice guidelines (CPGs) are intended to facilitate choice.  The National 
Academy of Medicine (formerly called the Institute of Medicine; IOM, 2011) defines CPGs as 
“statements that include recommendations intended to optimize patient care that are informed by 
a systematic review of evidence and an assessment of the benefits and harms of alternative care 
options (p. 4).”  Although they make recommendations for how a given problem should be 
treated, guidelines are not mandates:  “Rather than dictating a one-size-fits-all approach to 
patient care, CPGs are able to enhance clinician and patient decision-making by clearly 
describing and appraising the scientific evidence and reasoning (the likely benefits and harms) 
behind clinical recommendations, making them relevant to the individual patient encounter (p. 
1).”  Guidelines support, but do not dictate, decision-making. 
Since the initial formalization of the diagnostic criteria for posttraumatic stress disorder 
(PTSD) in the Diagnostic and Statistical Manual (DSM)-III (American Psychiatric Association, 
1980), guidelines for treating PTSD have been developed and revised as the evidence on 
treatment has evolved.  In 2011, a seminal report by the IOM (2011) significantly changed the 
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criteria for developing trustworthy guidelines.  According to the report, guidelines should (1) be 
based on a systematic review of evidence; (2) be developed by experts from multiple disciplines 
and include stakeholder input; (3) take patient subgroups and preferences into consideration; (4) 
be based on a transparent process that reduces bias and conflict of interest; (5) provide ratings of 
the quality of evidence and strength of outcomes; and (6) be revised in order to maintain 
currency as new evidence emerges.  One of the most significant implications of these 
recommendations is the emphasis on evidence, rather than clinical consensus, as a basis for 
making recommendations. 
In 2010, Forbes and colleagues (Forbes et al., 2010) published a “guide to guidelines” in 
order to synthesize the recommendations and help readers understand the similarities and 
differences among the then available guidelines. This article is an update to that guide, focusing 
on recent guidelines from the American Psychological Association (APA, 2017), the 
International Society for Traumatic Stress Studies (ISTSS, 2018), the National Institute for 
Health and Care Excellence (NICE, 2018), the Phoenix Australia Centre for Posttraumatic 
Mental Health (Phoenix Australia, 2013), and the US Departments of Veterans Affairs and 
Defense (VA/DoD, 2017). The aim of this article is to review, compare, and contrast the 
methodologies and recommendations of these five clinical practice guidelines for PTSD (see 
Table 1) with the goal of helping clinicians make decisions about the use of the recommended 
treatments.   
PTSD Clinical Practice Guideline Methodologies 
Of the guidelines reviewed, two were from professional associations, the APA and ISTSS 
(which is international).  The other three were developed by national organizations, spanning 
three continents. Phoenix Australia (formerly the Australian Centre for Posttraumatic Mental 
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Health) is a non-profit organization that collaborates with the Departments of Veterans’ Affairs 
and Defence in Australia. NICE is a public organization that creates national guidance on 
physical and mental health services and social care in the United Kingdom.  And, the VA/DoD 
guideline was a collaborative effort between two US governmental agencies. In earlier 
guidelines, some recommendations were made based on consensus expert opinion, rather than a 
reliance on evidence.  This changed dramatically in the recently completed guidelines reviewed 
here resulting in some changes in the recommendations. For example, in the VA/DoD guideline, 
the reliance on evidence for making recommendations reduced the number of recommendations 
from 213 in the 2010 document to 40 in the 2017 update.  
Scope of Review 
Table 2 includes the basic characteristics of the five guidelines, including the scope of 
each.  Four guidelines were updates (NICE was a partial update) to previous versions while one, 
the APA guideline, was a new addition. There was considerable consistency in methodology 
across the guidelines, likely due to the IOM report and standards (IOM, 2011).  For example, 
each guideline was overseen by a multidisciplinary panel of identified experts and there was a 
transparent process for the selection of panel members.  Efforts were also taken to minimize 
conflicts of interests (COIs) in members; each of the guidelines required members to disclose 
financial COIs that had the potential to affect their evaluation of the evidence.  All except the 
VA/DoD guideline required the disclosure of intellectual COIs in which a member’s point of 
view might affect the ability to judge evidence regarding a particular treatment method and make 
recommendations.  The APA guideline took the strictest approach to COI.  While other 
guidelines required members to declare their COIs, APA stated that “no panel members were to 
be singularly identified with particular interventions nor were they to have significant known 
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financial conflicts that would compromise their ability (or appearance thereof) to weigh evidence 
fairly.” (APA, 2017, p. 19). In essence, this meant that developers of specific PTSD treatments 
were not members of  the APA guideline panel.  
Each guideline process began with the identification of a series of key questions (a 
process known as “scoping”) that the guideline members (and in the case of ISTSS, its members) 
agreed were most relevant to their constituents. These questions became the focus of the 
evidence review and the basis for generating recommendations.  A guideline would therefore not 
necessarily make a recommendation about group versus individual treatment unless the 
comparative effectiveness of group versus individual treatment for PTSD was queried as a key 
question.   
All five guidelines received input from individuals with PTSD on these key questions. 
Forbes and colleagues (2010) make no mention of this type of input in the previous guidelines. 
Individuals with PTSD had more involved roles in the development of the Phoenix guideline, for 
which they also provided feedback on the recommendations, and the APA and NICE guidelines, 
for which they were full voting committee members.  Each guideline also provided an 
opportunity for external review.  Typically, the guideline was posted on the internet for several 
weeks during which comments from reviewers (professionals and interested members of the 
general public) were accepted.  An exception was ISTSS, which was only open to comments 
from its own members.   
In most cases (APA, ISTSS, Phoenix, and VA/DoD), an external independent evidence 
review was conducted to inform each key question.  If the key question was an update from a 
previous recommendation, the evidence review was typically limited to only those studies 
published since the previous guideline.  APA based its evidence review on Jonas et al. (2013) 
 8 
and then updated the search to include new articles published between 2012 and June 2016, but 
did not rate the new trials for risk of bias or conduct new meta-analyses. The group then rated the 
likelihood that the recommendation would change since 2013 based on the new evidence 
published after the Jonas et al. review. NICE conducted a partial update in which evidence from 
the 2005 guideline was carried forward and updated, and new reviews with unrestricted dates up 
to January, 2018 were added. For each key question a detailed search strategy using a specific 
methodology (e.g., Cochrane) was developed to identify all relevant articles. Information about 
the specific search strategies are available in each guideline. 
Study Characteristics 
Once key questions were identified, studies pertinent to each question were gathered. For 
characteristics of the studies see Table 3.  Identified studies that met specified criteria were 
included in the evidence review. Slight differences in search methodology and 
inclusion/exclusion criteria can have substantive effects on the final recommendations.  For 
example, whereas all five guidelines relied heavily on randomized controlled trials (RCTs), some 
also included systematic reviews (SRs) of RCTs.  The VA/DoD guideline prioritized SRs, which 
can cause challenges for evidence review as they may not include all the outcomes of interest, or 
they may classify treatment type in a manner that is inconsistent with how individual studies 
were classified in the guideline. The NICE and VA/DoD guidelines were the only ones to restrict 
inclusion of RCTs to those that included a minimum number of participants. Specifically, trials 
with fewer than 10 participants per arm were excluded. Although this could result in a failure to 
include potentially relevant studies, it helped to protect against undue influence given that small 
trials are more likely to be published if they find positive effects (Song, Hooper, & Loke, 2013).  
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There was also variability across the guidelines in defining the degree to which study 
participants had to meet criteria for PTSD.  For example, the VA/DoD guideline required that for 
a study to be included in the evidence review, at least 80% of participants had to meet criteria for 
PTSD. The systematic review that APA used as its evidence base did not restrict RCTs based on 
the percentage of participants who met PTSD criteria; however, all included studies had > 75% 
who met criteria for diagnosis. Only ISTSS specified that PTSD be diagnosed by structured or 
clinician interview.  Thus, even guidelines that ask the same key questions may result in 
differing recommendations due to differences in which studies were included.  
Finally, differences in how primary and secondary treatment outcomes were 
operationalized can also influence recommendations.  Although all of the guidelines prioritized 
PTSD symptom severity, the VA/DoD required that PTSD was measured by either the Clinician 
Administered PTSD Scale (Weathers, Blake, Schnurr, Kaloupek, Marx, & Keane, 2013) or 
another validated structured clinical interview to assess symptoms.  This is important because (1) 
self-reported changes in PTSD are typically larger than clinician ratings (e.g., Krystal et al., 
2016; Raskind et al., 2018; Resick et al., 2017; Schnurr et al., 2007) and (2) the guidelines 
reviewed different studies and study outcomes in their evidence reviews.  Another major 
difference was that whereas all the guidelines considered harms and adverse events, only APA 
and NICE considered these as a primary outcome.  Thus, APA and NICE recommendations may 
have been more likely than the other guidelines to downgrade a treatment due to harms and 
adverse events.  
Evaluations that Determine the Direction and Strength of Recommendations 
For each guideline, the evidence review relied on specific, previously published criteria 
to evaluate the quality of individual studies from different organizations: Agency for Healthcare 
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Research and Quality (AHRQ, 2008; APA), Cochrane (Higgins & Green, 2011; ISTSS and 
NICE), National Health and Medical Research Council (NHMRC, 2011; Phoenix) and U.S. 
Preventative Services Task Force (USPSTF, 2015; VA/DoD). Each evidence review had a 
formal system for evaluating study quality (see Table 4). Despite using different methodologies, 
there was general consensus across the guidelines on what these ratings took into account, even 
if they used different wording. For example, each considered selection, attrition, and detection 
biases. For four out of the five guidelines, the complete evidence review is publicly available to 
download; the VA/DoD guideline provides a briefer evidence table that includes the study 
references for each recommendation. 
After evaluating individual studies, the review groups evaluated the overall body of 
evidence for each key question. Again, there was considerable consistency across the guidelines 
in regard to the criteria used to make the rating.  Three guidelines (ISTSS, NICE, and VA/DoD,) 
used Grading of Recommendations Assessment, Development and Evaluation (GRADE; 
Andrews et al., 2013), APA used the AHRQ Methods Guide for Comparative Effectiveness 
Reviews (Viswanathan et al., 2012) which is based on GRADE, and Phoenix used NHMRC 
procedures (NHMRC, 2011). Examples of the criteria used to make the overall rating were risk 
of bias, consistency, directness, and precision. Risk of bias, as noted above, includes adequacy of 
randomization, differential attrition, and measurement bias. Consistency is the degree to which 
study findings are the same across the body of evidence.  Directness is the degree to which the 
tested intervention compares to the primary interest.  Precision has to do with the confidence 
interval associated with the estimate of the effect where a tighter confidence interval indicates a 
more precise effect.  
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Based on these factors, the overall body of evidence for each key question was rated as 
high, moderate, low, or very low (see Table 5).  High quality evidence means that what is known 
about the effect of the treatment in question is not likely to change with the addition of more 
research, thus patients and providers can have the most confidence or trust in the evidence.  
Moderate quality evidence means additional research could change the estimate of the effect, so 
patients and providers can have some, although not full, confidence in the research.  Low or very 
low quality is when there is uncertainty in the effect. 
Once the quality of the evidence was determined, each guideline also considered other 
relevant factors as part of determining the strength of the evidence before making specific 
recommendations.  Such factors included the balance of desirable and undesirable outcomes 
(including harms and adverse events), patient values and preferences, generalizability of a 
treatment to subgroups, feasibility and acceptability.  For example, an effective treatment might 
receive a lower recommendation if it has serious side effects.  A treatment that could be 
delivered by video teleconferencing might receive a higher rating if committee members had 
reason to believe patients would prefer the flexibility of not having to travel to the clinic or 
provider for treatment.  Only one guideline, NICE, directly considered the cost-effectiveness of 
treatments.  
Grading the Strength of the Recommendation 
The last step in the process was determining a recommendation and developing a 
statement that included a specification of the strength of the recommendation. In order to make 
the recommendations comparable across the different guidelines for the purpose of this review, 
we (the authors1) developed a common nomenclature to describe the strength of the 
 
1 Authors included members from each of the represented guidelines 
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recommendations across guidelines (see Table 6).  We also made decisions about how to align 
the various levels across the guidelines since some guidelines had more levels than others.  APA, 
NICE and VA/DoD had only two levels to choose from and recommendations could be either for 
or against.  In contrast, ISTSS had four levels (two of which could be for or against) and Phoenix 
had four levels, as well as a clinical recommendation. This meant that ISTSS and Phoenix had 
more opportunity to make recommendations about treatments for which there was a lower level 
of support. Four of the five guidelines (all but NICE) also allowed for a formal insufficient 
evidence recommendation. Given the variability in levels and naming conventions, in some cases 
what we categorized as “moderate” was rated as “weak” by the specific guideline, but weak does 
not equate with low evidence. It is also important not to confuse strength of recommendation 
with strength of evidence available to make that recommendation.  For example, ISTSS 
recommended several medications as low effect interventions because strong evidence was 
found that they were beneficial to people with PTSD but the magnitude of symptom change was 
lower than for the strongly recommended psychological treatments.  
PTSD Clinical Practice Guideline Recommendations 
Although there are many consistencies in recommendations across the five guidelines, the 
variability in key questions and methodology resulted in some differences. Below we summarize 
the primary PTSD treatment recommendations across guidelines and highlight key similarities 
and differences. We also present recommendations on group, couples, internet-based, 
complementary and integrated, and non-pharmacologic biological treatments as a primary 
treatment for PTSD.  We do not present recommendations on prevention, Acute Stress Disorder, 
assessment, or specific PTSD symptoms.  We also do not include recommendations related to 
children, adolescents, or families. The APA, Phoenix and VA/DoD guidelines also include 
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narrative descriptions summarizing the recommendations.  The ISTSS guideline will have an 
accompanying book with chapters dedicated to the recommended treatments.  The NICE 
guideline did not include accompanying summaries. 
Treatment Initiation Recommendations for Individual Psychotherapies and 
Pharmacotherapies 
A new addition to some of the clinical practice guidelines were recommendations that 
focused on prioritizing the use of some types of treatment over other types (see Table 7a).  Three 
out of five guidelines had specific recommendations to deliver trauma-focused psychotherapies 
over pharmacotherapies (NICE, Phoenix, and VA/DoD).  This is different from separate 
recommendations that give higher ratings to one treatment over another. For example, in the 
VA/DoD guideline, both specific trauma-focused psychotherapies and specific 
pharmacotherapies were given the highest recommendation, but the guideline also recommended 
these trauma-focused psychotherapies over the pharmacotherapies. Similarly, although some 
medications were given a stronger recommendation than some non-trauma-focused treatments, 
the VA/DoD guideline specified that there was insufficient evidence to recommend whether to 
deliver an individual non-trauma-focused psychotherapy or medications in cases where an 
individual trauma-focused psychotherapy was not available or preferred or was not effective. It 
should be noted that the two guidelines that did not have treatment prioritization 
recommendations (APA and ISTSS) still gave stronger ratings to trauma-focused treatments than 
they did to medications.  Due to methodological differences between psychotherapy trials and 
medication trials that might influence treatment effect magnitude (Huhn et al., 2014), the APA 
committee did not believe there was sufficient evidence, in the absence of head-to-head trials, to 
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support prioritizing psychotherapy over medications. However, the APA guideline did include 
comparative effectiveness recommendations (although they are not presented in this manuscript). 
Individual Psychotherapy Recommendations for PTSD 
Recommendations related to psychotherapy for PTSD are included in Table 7b. All five 
guidelines gave a strong recommendation to trauma-focused psychotherapies (TFTs). In some 
cases, the guidelines elected to recommend the overall category of TFTs, while in others they 
named the treatments they were recommending.  In either case all included Prolonged Exposure 
therapy (PE), Cognitive Processing Therapy (CPT) and trauma-focused cognitive behavioral 
therapy (TF-CBT) and some include other trauma-focused treatments as well. Four of the five 
guidelines also gave Eye Movement Desensitization and Reprocessing (EMDR) a strong 
recommendation.  The exception was the APA guideline, which gave EMDR a moderate rating2.  
There was less consistency in ratings across other psychotherapies.  Among trauma-
focused therapies the VA/DoD guideline gave a strong recommendation to Brief Eclectic 
Psychotherapy, which was rated as moderate by APA and insufficient by ISTSS. The VA/DoD 
guideline also gave a strong recommendation to Narrative Exposure Therapy (NET) which was 
rated as moderate by both APA and ISTSS, and to written narrative exposure which was not 
specified at all in other guidelines.  APA gave a strong recommendation to general cognitive 
behavioral therapy (CBT), but a closer look at which treatments were included in this category 
suggests that the majority of these studies were in fact TF-CBTs. 
Three of the guidelines (VA/DoD, Phoenix, and ISTSS) provided non-trauma-focused 
options at various levels of support. The VA/DoD guideline gave a moderate recommendation to 
 
2 EMDR was rated as having moderate strength of evidence for loss of PTSD diagnosis; however, loss of PTSD 
diagnosis was considered an important, but not critical outcome, by the APA panel for all recommendation decisions 
for all treatments. 
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Stress Inoculation Training (SIT), Present-Centered Therapy (PCT) and Interpersonal 
Psychotherapy.  The Phoenix guideline gave a low recommendation to non-trauma-focused 
treatments such as SIT and suggested only using them when non-trauma-focused treatments have 
been tried.  ISTSS gave a moderate recommendation to CBT without a trauma focus and PCT. 
Three of the guidelines (APA, ISTSS, VA/DoD) provided insufficient recommendations 
for certain treatments, indicating that there is not enough research to support their use for the 
treatment of PTSD at this time.  These included popular treatments such as Seeking Safety, 
Dialectical Behavior Therapy, Acceptance and Commitment Therapy, and Skills Training in 
Affect and Interpersonal Regulation.  This does not mean that the treatments were ineffective, 
but rather that there was insufficient evidence to show they were effective for treating PTSD at 
this time. NICE reviewed a long list of additional psychotherapies but did not make any formal 
insufficient recommendations. 
Pharmacotherapy Recommendations for PTSD 
As seen in Table 7c there was general agreement as to which medications were most 
effective for treating PTSD.  Guidelines that named medications (APA, ISTSS, and VA/DoD) 
supported the use of sertraline, paroxetine, fluoxetine and venlafaxine.  The Phoenix guideline 
recommended the class of selective serotonin reuptake inhibitors (SSRIs), while the NICE 
guideline named SSRIs (and cited sertraline as an example) as well as venlafaxine. There was 
less consistency, however, in the strength of those pharmacotherapy recommendations. Across 
the guidelines, the most effective medications were ranked as a strong recommendation by only 
one guideline (VA/DoD), a moderate by two (APA and NICE), and a low by two (ISTSS and 
Phoenix).  The lack of agreement among the guidelines may be due to differences in estimated 
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treatment effect sizes and confidence intervals based on the RCTs that were included in the 
meta-analyses and differences in how strongly the guidelines weighted harms (e.g., side effects). 
Only two guidelines (NICE and VA/DoD) offered second line pharmacotherapy 
recommendations. The VA/DoD guideline included nefazodone, imipramine, and phenelzine. 
The NICE guideline also gave a moderate recommendation for antipsychotics (with risperidone 
cited as an example) following non-response to other drug or psychological treatments, but only 
as an augmentation to psychological therapies and in the context of disabling symptoms and 
behaviors. The ISTSS guideline also gave an emerging recommendation to quetiapine. The 
VA/DoD guideline was the only one that made specific recommendations against a 
pharmacotherapy (see Table 7c for a complete list). Strong “against” recommendations were 
generally due to negative results and/or harmful side effects.  Three of the guidelines made a 
recommendation to note which medications had insufficient evidence. Although NICE did not 
make a formal insufficient recommendation, the guideline committee considered a long list of 
additional medications for which they determined there was not sufficient evidence to support. 
APA also considered some medications for which they chose not to make a formal 
recommendation. 
Other Recommendations for PTSD 
Three of the five guidelines (ISTSS, Phoenix, and VA/DoD) assessed group treatments 
(see Table 7d).  The ISTSS guideline provided a range of recommendations from a moderate 
recommendation for group CBT with a trauma-focus to an emerging recommendation for 
combined group and individual CBT with a trauma focus.  They also gave group interpersonal 
therapy, group stabilizing treatment, and group supportive counselling insufficient 
recommendations.  The Phoenix guideline gave a low recommendation for group CBT (with or 
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without a trauma-focus) but only as an adjunct to treatment.  The VA/DoD guideline gave a 
moderate recommendation but only as compared to no treatment at all, based on a literature 
review showing that group was less effective than individual therapy.  Although the NICE 
guideline found limited evidence in support of trauma-focused group therapy, a formal 
recommendation was not made because group was not determined to be clinically or cost 
effective. 
Only two guidelines made recommendations regarding couples therapy (see Table 7d).  
The VA/DoD guideline gave both trauma-focused and non-trauma focused couples therapy an 
insufficient recommendation.  The ISTSS guideline, however, gave trauma-focused couples 
therapy an emerging recommendation.  
There was moderate consistency across guidelines with respect to internet-based 
interventions (see Table 7d). Three guidelines (ISTSS, NICE and VA/DoD) gave a moderate 
recommendation for internet-based interventions that included therapist support. The Phoenix 
guideline gave a low recommendation but did not require the support of a therapist.  
With respect to complementary and integrated health interventions, there was the greatest 
support for acupuncture. The ISTSS guideline gave acupuncture an emerging recommendation, 
the Phoenix guideline gave it a very low recommendation, and the VA/DoD guideline gave it an 
insufficient recommendation as a primary treatment for PTSD. The NICE guideline considered 
exercise and acupuncture but did not make a formal recommendation. 
Finally, three of the guidelines considered non-pharmacologic biological treatments.  The 
NICE and VA/DoD guidelines gave an insufficient recommendation to repetitive transcranial 
magnetic stimulation (rTMS).  The VA/DoD guideline also gave electroconvulsive shock 
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therapy, hyperbaric oxygen, stellate ganglion, and vagal nerve stimulation insufficient 
recommendations.  ISTSS gave TMS an emerging recommendation. 
Discussion and Conclusion 
The goal of this review was to compare and contrast methodologies and 
recommendations across five recently published PTSD clinical practice guidelines. It is clear that 
since the previous round of clinical practice guidelines for PTSD, there is now a more rigorous 
approach to guideline development methodology and that the field is making progress by moving 
towards evidence-based guidelines.  The IOM (2011) report in 2011 had an impact on both 
defining what a clinical practice guideline is and the methods used in their development. In fact, 
many guidelines are moving toward using the exact same methodology.  For example, the 
majority of the guidelines reviewed here used GRADE to assess the strength of evidence for 
making recommendations.  As a result, the recommendations across the PTSD guidelines were 
fairly consistent.   
All of the guidelines gave the highest recommendations to trauma-focused 
psychotherapies (including EMDR in 4 of the 5 guidelines) and all agreed that SSRIs (either 
specific ones or the whole class) were the most effective medications. All except APA agreed 
that the best psychotherapies were more effective than the best medications; the APA panel 
concluded that comparative effectiveness could not be assessed in the absence of head-to-head 
trials.  These recent guidelines were the first ones to make recommendations regarding how to 
prioritize treatment modalities relative to each other.  All of the ones that had recommendations 
regarding prioritization recommended trauma-focused therapy over medication. These 
recommendations were based on meta-analyses because there were so few head-to-head 
comparisons of a single medication with a single psychotherapy. Future guidelines may be able 
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to base recommendations regarding how to prioritize treatments on studies that directly compare 
different evidence-based treatment modalities to one and other.  
Perhaps the biggest methodological difference among the guidelines was whether they 
recommended treatments by name (e.g., PE), type (e.g., trauma-focused therapy), or both.  Each 
guideline committee had to make a decision as to whether the trauma-focused treatments were 
similar enough that they should be recommended as a class rather than individually. If the core 
components of the treatments were thought to be what makes them effective (e.g., exposure and 
cognitive restructuring) then recommending the class of treatments (e.g., cognitive behavioral 
therapy) may make sense. The VA/DoD guideline based its definition of “trauma-focused” on 
Schnurr (2017; i.e., “any therapy that uses cognitive, emotional, or behavioral techniques to 
facilitate processing a traumatic experience and in which the trauma focus is a central component 
of the therapeutic process). However, the committee also chose to list those specific treatments 
for which there was the strongest support. The NICE guideline also recommended individual 
trauma-focused CBT interventions as a class but listed some specific interventions as examples 
of that class. 
The same issue arose with medications. Recommendations for a class of medications 
implied that all medications within the class had both similar efficacy and similar side effect 
profiles. Some guidelines determined that those criteria were met and recommended the class of 
SSRIs while others named only specific SSRIs given evidence of varying levels of efficacy 
within the class (e.g., Watts et al., 2013). 
There was variability in the support of some treatments such as BEP, NET, and IPT, 
where some guidelines gave them strong recommendations and others gave them weak or 
emerging/insufficient recommendations.  Group treatments, as well as some other popular 
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treatments such as SS and ACT, received little support across the guidelines (except in the ISTSS 
guideline which gave group treatment with a trauma focused a moderate recommendation). 
Couples treatments and TMS received emerging/insufficient recommendations.  Acupuncture 
was the most supported CAM intervention, but received either a very low recommendation or an 
emerging/insufficient recommendation.  Finally, therapist guided internet-based interventions 
received mostly moderate recommendations; the Phoenix guideline gave it a low 
recommendation but this was likely due to fact that their literature review did not include RCTs 
after 2011.  
Given the increasing number of treatment options, how does a clinician choose among 
the most effective treatment options, especially in a situation when providers may lack training 
and competency in these treatments? Several of the guidelines specifically recommended shared 
decision making (SDM). In SDM, the patient and provider work together to review treatment 
options to determine which treatment best meets the patient’s needs and preferences.  Part of that 
process involves not only a discussion about which treatments are most effective, but also 
whether they can be provided, and where they can be accessed, and any harms or burdens 
associated with them.  Thus, patients are making an informed choice about what treatments may 
work best for them and may even choose a treatment that does not have the highest level of 
support. New comparative effectiveness trials will also be useful in helping clinicians and 
patients make treatment decisions. Clinicians may also make choices based on which of the 
treatments they have training in and resources to deliver. Ideally, CPGs are used to inform policy 
and resource allocation to make the most highly recommended treatments available. However, in 
the short term, or in a situation where there are multiple effective options, not all may be 
available.  
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Clinicians often desire more specific information about what treatments work for the 
patients they see in clinical practice based on a concern that research participants do not fully 
resemble clinical populations. Many of the RCTs included in the evidence reviews were based 
on diverse and complex patients and are therefore generalizable to a wide range of patients. 
Thus, the guidelines generally support the use of these treatments with all patients and should not 
be limited to only those with PTSD and no other comorbidities or complexities. In fact, the NICE 
and VA/DoD guidelines had a specific recommendation stating that the presence of co-occurring 
disorders should not prevent patients from receiving recommended treatments. A limitation, 
however, is that the guidelines are unable to make specific recommendations about whether 
some treatments work best for different subgroups of patients because few trials performed 
subgroup analyses or were powered to do so. In addition, some providers may also be concerned 
that trauma-focused interventions in particular may interfere with the therapeutic alliance.  A 
recent meta-analysis, however, confirmed that while there is a positive relationship between 
alliance and outcome, this effect was not moderated by type of intervention (Fluckiger, Del Re, 
Wampold, & Horvath, 2018).  
It is notable that there are so many PTSD practice guidelines. How does a clinician 
determine which guideline to use? In some cases, clinicians may choose based on the 
constituency of which they are a part.  For example, if they work in the VA, they may follow the 
VA/DoD guideline, whereas if they are in Australia, they may defer to the Phoenix guideline. It 
is worth asking if in fact all are needed.  Considerable resources are put forth in conducting the 
evidence reviews, making the recommendations, and writing the guidelines.  And almost as soon 
as the guidelines are released, the process of updating begins.  Is there a better way?  Perhaps in 
the future, different entities and organizations would do better to collaborate on producing joint 
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guidelines. While it is likely that each organization will want to continue to produce its own 
guideline, the National Center for PTSD has recently committed to producing a public database 
of all PTSD treatment studies that might make it easier to identify the relevant literature and 
conduct the evidence review.  When completed it will be available at www.ptsd.va.gov. 
Although treatment guidelines have existed for a long time now, many providers are not 
aware that they exist.  One survey of 463 community providers in Texas found that only half 
were aware of any clinical practice guideline for PTSD (Finley, Noel, et al., 2018).  In a related 
study, while half of providers reported using an evidence-based treatment for PTSD, far fewer 
said they used the core components of those treatments, suggesting they are not delivering them 
with fidelity (Finley, Mader, et al., 2018). For practice guidelines to be useful, they need to be 
widely disseminated and training and support are required for providers to deliver the treatments 
with fidelity. 
Several limitations of clinical practice guidelines have already been mentioned.  For 
example, the guidelines are limited by the original scoping questions and the current literature. 
Few trials exist that examine how the treatments respond with various subgroups or how the 
treatments compare to one another.  Recommendations on emerging interventions are also 
limited because of the lack of available randomized controlled trials, but that does not mean 
these interventions are ineffective.  Of note, ISTSS in particular made specific recommendations 
for treatments with emerging evidence as a way to recognize them. There are also new 
treatments being developed and new delivery mechanisms (such as telehealth and internet) being 
evaluated to determine if they are effective. Given that the literature is always growing, it is 
important that guidelines are updated regularly.  For example, the VA/DoD guidelines are 
intended to be updated every five years.  
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In closing, we, as authors of this review and members of the various clinical practice 
guideline committees, want to end by revisiting the goal of CPGs, which should drive practice 
and may or may not support the practices that clinicians are already delivering.  But they are also 
not policies in and of themselves and should not blindly be followed.  Instead, CPGs should 
support clinicians and patients in diagnostic and treatment decision-making.  They provide 
critical information about the effectiveness of specific treatments based on rigorous methodology 
and should be used as a starting place for a conversation about treatment choice.  Along with 
patients’ preferences and values, and clinicians’ experiences, practice guidelines are a critical 
component to ensure patients receive the best care possible.  
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Table 1  
 
The Five Most Recent Clinical Practice Guidelines for Posttraumatic Stress Disorder 
 
Author, Date Guideline Name URL 
American Psychological 
Association, 2017 
Clinical Practice Guideline for the 
Treatment of PTSD in Adults 
https://www.apa.org/ptsd-guideline/ptsd.pdf 
 
International Society for 
Traumatic Stress 
Studies, 2018 
ISTSS Posttraumatic Stress Disorder 
Prevention and Treatment 
Guidelines: Methodology and 
Recommendations 
https://www.istss.org/getattachment/Treating-
Trauma/New-ISTSS-Prevention-and-Treatment-
Guidelines/ISTSS_PreventionTreatmentGuidelines_FNL.p
df.aspx 
National Institute for 
Health and Care 
Excellence, 2018 
Post-traumatic Stress Disorder: 
Management (update) 
https://www.nice.org.uk/guidance/ng116/resources/posttra
umatic-stress-disorder-pdf-66141601777861 
Phoenix Australia, 2013 Australian Guidelines for the 
Treatment of Acute Stress Disorder 
and Posttraumatic Stress Disorder 
https://www.phoenixaustralia.org/wp-
content/uploads/2015/03/Phoenix-ASD-PTSD-
Guidelines.pdf 
Department of Veterans 
Affairs/Department of 
Defense, 2018 
Clinical Practice Guideline for the 
Management of Posttraumatic Stress 
Disorder and Acute Stress Disorder 
https://www.healthquality.va.gov/guidelines/MH/ 
ptsd/VADoDPTSDCPGFinal012418.pdf 
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Table 2  
 
Scope of Review 
 
 APA, 2017 ISTSS, 2018 NICE, 2018 Phoenix, 2013 VA/DoD, 2018 
Type of review New Update from 2005 Update from 2005 Update from 2007 Update from 2010 
Country United States International United Kingdom Australia United States 
Focus of review Key questions Key questions Key questions  Key questions Key questions  
Developed by Multidisciplinary panel Multidisciplinary panel Multidisciplinary panel Multidisciplinary panel Multidisciplinary panel 
Selection of panel 
members 
Chair and members 
selected by the Advisory 
Steering Committee of 
APA 
Identified by Chair of 
ISTSS Guidelines 
Committee and approved 
by ISTSS Board of 
Directors  
 
 
NICE committee members 
recruited through an 
application process  
• Core development group 
selected by co-chairs 
• Multidisciplinary 
reference group nominated 
by professional 
associations 
 
• Chairs selected by VA 
and DoD 
• Panel members selected 
by chairs 
 
 
Type of conflict of 
interest considered 
Financial and intellectual Financial and intellectual Financial and intellectual Financial and intellectual  Financial  
Involvement of people 
with PTSD 
Voting panel members Provided input on key 
questions 
Voting panel members Provide input on key 
questions and 
recommendations (non-
voting) 
Provided input on key 
questions 
 
Community 
involvement 
Public comments (60 
days) 
Comment by ISTSS 
members and ISTSS 
Board (4 weeks) 
Registered stakeholder 
review during public 
consultation period (6 
weeks) 
Public comments (6 
weeks) 
Public comments (about 3 
weeks) 
Time period covered 
and who conducted the 
review 
Agency for Healthcare 
Research and Polity 
(AHRQ) (Jonas et a., 
2013) covering 1980-June 
2013. 
AHRQ review 
supplemented by updated 
search conducted by panel 
sub-group, 2013-2016 
• 1980-March 2018 
• Previous reviews 
updated with new searches 
covering January 2008 to 
March 2018 
• 1980-January 2018 
(September 2017 for 
qualitative reviews) 
• Previous updated with 
new search covering 
2005-2018 
• 1996-October 2011 
• Previous reviews 
updated with new searches 
covering 2005 to 2011 
(unless new question and 
then 1996-2011) 
• 1980-March 2016 
• Previous reviews 
updated with new search 
covering 2009 to 2016 
Note. APA = American Psychological Association; ISTSS = International Society for Traumatic Stress Studies; NICE = National Institute for Health and Care Excellence; 
VA/DoD = Department of Veterans Affairs and Department of Defense.  
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Table 3  
 
Study Characteristics 
 
 APA, 2017 ISTSS, 2018 NICE, 2018 Phoenix, 2013 VA/DoD, 2018 
Nature of studies 
examined 
• Primarily systematic 
reviews of RCTS and 
individual RCTs 
• Key questions related to 
harms and patient 
preferences included other 
study designs as well as 
consideration of consumer 
and clinician experience  
RCTs • Primarily systematic 
reviews of RCTs and 
individual RCTs 
• One question allowed 
qualitative and mixed 
methods studies 
• Primarily systematic 
reviews of RCTs and 
individual RCTs 
• If fewer than two RCTs  
other study designs were 
included 
• Primarily systematic 
reviews of RCTs and 
individual RCTs (N>20) 
•One key question allowed 
cohort study. 
English language 
studies only 
Yes Yes Yes Yes Yes 
Study Treatment 
Target 
PTSD  Prevention, ASD, and 
PTSD 
Prevention, ASD, PTSD, 
family members and care 
givers of those with PTSD 
Prevention, ASD, and 
PTSD 
Prevention, ASD, and 
PTSD 
Patient, Population, 
or Problem 
Adults with PTSD  Adults with ASD or PTSD 
(>70% dx via structured or 
clinician interview), and 
adolescents and children 
(with full or partial PTSD) 
Adults, adolescents, 
children with PTSD 
diagnosis or above 
threshold on a validated 
scale 
Adults with ASD or PTSD 
(>70% dx), adolescents and 
children  
 
Adults with ASD or PTSD 
(>80% dx) 
 
Target Interventions • Psychological  
• Pharmacological  
• Psychological  
• Pharmacological  
• Non-pharmacologic 
biologic  
• Complementary and 
integrative health  
• Other 
• Psychological 
• Pharmacological 
• Non-pharmacologic 
biologic 
• Complementary and 
integrative health  
• Psychosocial  
• Technology based 
• Support for family and 
caregivers 
• Psychological  
• Pharmacological  
• Repeated transcranial 
magnetic stimulation 
• Psychosocial 
rehabilitation  
• Acupuncture 
• School based  
• Psychological  
• Pharmacological  
• Non-pharmacologic 
biologic  
• Complementary and 
integrative health  
• Collaborative care/ 
integrated care 
• Technology based  
Comparison 
Interventions 
Any Any Any Any Any 
Primary Outcomes 
of Interest 
• PTSD symptom severity 
• Other: serious harms or 
adverse events 
• PTSD symptom severity • PTSD symptom severity 
• Other: adverse events 
(retention/dropout rate), 
loss of diagnosis/remission, 
findings from qualitative 
studies 
• PTSD symptom severity  
 
 
• PTSD symptom severity 
(based on CAPS or other 
validated structured clinical 
interview) 
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• Other: adverse events, 
retention/dropout rate, loss 
of diagnosis/remission  
Secondary Outcome 
of Interest 
APA  • Loss of 
diagnosis/remission  
• Other: comorbid 
symptoms, quality of life, 
functional status, adverse 
events  
• Other: comorbid 
symptoms, dissociative 
symptoms, quality of life, 
functional status 
• PTSD diagnosis 
• Other: symptom change, 
functional status, and 
tolerability 
• Other: comorbid 
symptoms, dissociative 
symptoms, functional status 
Setting  All All All All  All  
 
Note. APA = American Psychological Association; ASD = Acute Stress Disorder; ISTSS = International Society for Traumatic Stress Studies; NICE = National Institute for Health 
and Care Excellence; PTSD = Posttraumatic Stress Disorder; RCT = Randomized Controlled Trials; VA/DoD = Department of Veterans Affairs and Department of Defense. 
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Table 4: Criteria for Evaluating Study Quality 
 
APA, 2017 ISTSS, 2018 NICE, 2018 Phoenix, 2013 VA/DoD, 2018 
AHRQ Methods Guide for 
Comparative Effectiveness 
Reviews (Viswanathan et al., 
2012) 
Cochrane Collaboration Tool 
(Higgins et al., 2011) 
Cochrane Collaboration Tool 
(Higgins & Green, 2011)  
National Health and Medical 
Research Council (NHMRC, 
2000) 
U.S. Preventative Services Task 
Force Method (USPSTF, 2015) 
• Comparable groups 
• Adequate randomization 
• Allocation concealment 
•  Comparable groups at 
baseline 
• Masked assessment 
• Masked providers 
• Masked patients 
• Overall attrition  
• Differential attrition  
• Intention to treat is used 
• Appropriate methods for 
handling missing data 
• Reliable and valid measures 
• Treatment fidelity based on 
independent raters 
 
• Random sequence generation 
(selection bias) 
• Allocation concealment 
(selection bias) 
• Masking of participants and 
personnel (performance bias) 
• Masking of outcome 
assessment (detection bias) 
• Incomplete outcome data 
(attrition bias) 
• Selective reporting (reporting 
bias)  
•  Other bias 
 
• Random sequence generation 
(selection bias) 
• Allocation concealment 
(selection bias) 
• Masking of participants and 
personnel (performance bias) 
• Masking of outcome 
assessment (detection bias) 
• Incomplete outcome data 
(attrition bias) 
• Selective reporting (reporting 
bias)  
•  Other bias 
 
• Comparable groups 
• Adequate randomization 
• Allocation concealment 
• Masking of outcome assessor 
assessment 
• Masking of providers 
• Masking of patients 
• Intention to treat is used  
• Overall attrition  
 
• Initial assembly of comparable 
groups: 
• For RCTs: adequate 
randomization, including first 
concealment and whether 
potential confounders were 
distributed equally among 
groups 
• Maintenance of comparable 
groups (includes attrition, cross-
overs, adherence, 
contamination) 
• Important differential loss to 
follow up or overall high loss to 
follow up 
• Measurements: equal, reliable, 
and valid (includes masking of 
outcome assessment) 
• Clear definition of 
interventions 
• All important outcomes 
considered 
• Analysis: adjustment for 
potential confounders for cohort 
studies or intention-to-treat 
analysis for RCTs 
 
 
Note. AHRQ = Agency for Healthcare Research and Quality, APA = American Psychological Association, ISTSS = International Society for Traumatic Stress Studies, NICE = 
National Institute for Health and Care Excellence, VA/DoD = Department of Veterans Affairs and Department of Defense. 
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Table 5  
 
Evaluating the Body of Evidence  
 
 APA, 2017 ISTSS, 2018 NICE, 2018 Phoenix, 2013 VA/DoD, 2018 
High 
Quality 
Further research is very 
unlikely to 
change confidence in the 
estimate of effect 
Further research is very 
unlikely to change confidence 
in the estimate of effect 
 
Further research is very 
unlikely to change confidence 
in the estimate of effect 
 
Body of evidence can be 
trusted to guide practice  
 
Further research is very 
unlikely to change confidence 
in the estimate of effect 
 
Moderate 
Quality 
Further research may change 
our confidence in the 
estimate of the effect and 
may change the estimate 
Further research is likely to 
have important impact on our 
confidence in the estimate of 
effect and may change the 
estimate 
  
Further research is likely to 
have important impact on our 
confidence in the estimate of 
effect and may change the 
estimate 
  
Body of evidence can be 
trusted to guide practice in 
most situations 
Further research is likely to 
have important impact on our 
confidence in the estimate of 
effect and may change the 
estimate 
  
Low 
Quality 
Further research is likely to 
change confidence in the 
estimate of the effect and is 
likely to change the estimate 
Further research is very likely 
to have an important impact 
on confidence in the estimate 
of effect and is likely to 
change the estimate 
 
Further research is very likely 
to have an important impact 
on confidence in the estimate 
of effect and is likely to 
change the estimate 
 
Body of evidence provides 
some support for 
recommendation(s) but care 
should be taken in its 
application 
Further research is very likely 
to have an important impact 
on confidence in the estimate 
of effect and is likely to 
change the estimate 
  
Very Low 
Quality 
Any estimate of effect is very 
uncertain 
 
Any estimate of effect is very 
uncertain 
 
Any estimate of effect is very 
uncertain 
 
Body of evidence is weak 
and recommendation(s) must 
be applied with caution 
Any estimate of effect is very 
uncertain 
 
Note. APA = American Psychological Association, ISTSS = International Society for Traumatic Stress Studies, NICE = National Institute for Health and Care Excellence, 
VA/DoD = Department of Veterans Affairs and Department of Defense.
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Table 6 
 
Grading Strength of Recommendation 
 
 APA, 2017 ISTSS, 2018 NICE, 2018 Phoenix, 2013 VA/DoD, 2018 
Strong 
Recommendation 
 
Strong for/against (or “We 
recommend/recommend 
against offering this 
option…”)  
A Strong for/against 
recommendation  
Should be offered 
(“Offer/Do not offer”) 
Grade A  Strong for/against (or “We 
recommend/recommend 
against offering this 
option…”)  
Moderate 
Recommendation 
Weak for/against (or “We 
suggest /suggest against 
offering this option…”)  
A standard for/against 
recommendation  
Could be offered 
(“Consider/Do not 
consider”) 
Grade B Weak for/against (or “We 
suggest /suggest against 
offering this option…”)  
Low Recommendation Not applicable Intervention with low 
effect 
Not applicable Grade C Not applicable 
Very Low 
Recommendation  
Not applicable Not applicable  Not applicable Grade D  Not applicable 
Insufficient 
Recommendation 
No recommendation for or 
against (or “There is 
insufficient evidence…”)  
Insufficient Evidence to 
Recommend 
Not applicable: 
Recommend more research 
where insufficient evidence 
was found 
Consensus Points: used 
when a research question 
was asked of the data, but 
no evidence was 
forthcoming 
No recommendation for or 
against (or “There is 
insufficient evidence…”)  
Emerging 
Recommendation 
Not applicable Intervention with emerging 
evidence 
Not applicable Not applicable Not applicable 
Clinical 
Recommendation 
Not applicable Not applicable Not applicable Good Practice Points: used 
when the research question 
was not asked, often 
because the working party 
was confident that no 
evidence existed 
Not applicable 
Note. In order to make comparisons across the recommendations, the authors developed their own strength of recommendation categories.  
Note. APA = American Psychological Association; ISTSS = International Society for Traumatic Stress Studies; NICE = National Institute for Health and Care Excellence; 
VA/DoD = Department of Veterans Affairs and Department of Defense. 
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Table 7a. Treatment Prioritization Recommendations for Individual Psychotherapies and Pharmacotherapies for PTSD 
 
 APA, 2017 ISTSS, 2018 NICE, 2018 Phoenix, 2013 VA/DoD, 2018 APA, 2017 
Strong 
Recommendation 
  Recommend 
individual, 
manualized trauma-
focused CBT or 
EMDR (latter for 
non-combat-related 
trauma only) over 
other psychological, 
or pharmacological, 
interventions for the 
primary treatment of 
established PTSD 
  • We recommend 
individual, manualized 
trauma-focused 
psychotherapy over other 
pharmacologic and 
nonpharmacologic 
interventions for the 
primary treatment of PTSD 
• When individual trauma-
focused psychotherapy is 
not readily available or not 
preferred, we recommend 
pharmacotherapy or 
individual non-trauma-
focused psychotherapy. 
With respect to 
pharmacotherapy and non-
trauma-focused 
psychotherapy, there is 
insufficient evidence to 
recommend one over the 
other 
Moderate 
Recommendation 
  • Consider CBT 
interventions targeted 
at specific symptoms 
such as sleep 
disturbance or anger 
only if the person is 
unable or unwilling to 
engage in a trauma-
focused intervention 
or has residual 
symptoms are a 
trauma-focused 
intervention 
• Consider 
medications only if 
person has a 
preference for drug 
treatment, or as 
second-line 
Drug treatments for 
PTSD should not be 
preferentially used as 
a routine first 
treatment for adults, 
over trauma-focused 
cognitive behavioral 
therapy or Eye 
Movement 
Desensitization and 
Reprocessing 
  
 37 
augmentation 
treatment for 
disabling symptoms 
and behaviors 
 
Note. In order to make comparisons across the recommendations, the authors created their own strength of recommendation categories. Only rows for which there were 
recommendations were included in the table. In addition, the APA guideline offers recommendations based on comparative effectives such as a strong recommendation that 
clinicians offer either prolonged exposure or prolonged exposure plus cognitive restructuring when both are being considered and that clinician offer either venlafaxine ER or 
sertraline when both are being considered.  
Note. APA = American Psychological Association; ISTSS = International Society for Traumatic Stress Studies; NICE = National Institute for Health and Care Excellence; 
VA/DoD = Department of Veterans Affairs and Department of Defense. 
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Table 7b 
 
Individual Psychotherapy Recommendations for PTSD 
 
 APA, 2017 ISTSS, 2018 NICE, 2018 Phoenix, 2013 VA/DoD, 2018 
Strong 
Recommendation 
 
• Cognitive behavioral 
therapy   
• Prolonged exposure 
therapy 
• Cognitive processing 
therapy  
• Cognitive therapy 
 
• Trauma-focused cognitive 
behavioral therapy 
(undifferentiated) 
• Prolonged Exposure 
• Cognitive Processing 
Therapy 
• Cognitive Therapy 
• Eye Movement 
Desensitization and 
Reprocessing  
• Trauma-focused cognitive 
behavioral interventions  
• Cognitive Processing 
Therapy 
• Cognitive therapy for 
PTSD 
• Narrative exposure 
therapy 
• Prolonged Exposure 
• Eye Movement 
Desensitization and 
Reprocessing (more than 3 
months after non-combat-
related trauma) 
• Trauma-focused cognitive 
behavioral interventions 
• Eye Movement 
Desensitization and 
Reprocessing 
 
• Prolonged Exposure  
• Cognitive Processing 
Therapy 
• Eye Movement 
Desensitization and 
Reprocessing 
• Specific cognitive 
behavioral therapies for 
PTSD 
• Brief Eclectic 
Psychotherapy  
• Narrative Exposure 
Therapy  
• Written narrative exposure 
Moderate 
Recommendation  
• Brief Eclectic 
Psychotherapy  
• Eye Movement 
Desensitization and 
Reprocessing  
• Narrative Exposure 
Therapy 
• Cognitive behavioral 
therapy without a trauma 
focus 
• Narrative Exposure 
Therapy 
• Present-Centered Therapy 
 
Eye Movement 
Desensitization and 
Reprocessing (1-3 months 
after non-combat-related 
trauma) 
 
 • Interpersonal 
Psychotherapy 
• Present-Centered Therapy 
• Stress Inoculation 
Training  
 
 
Very Low 
Recommendation 
Not applicable Not applicable 
 
Not applicable Where symptoms have not 
responded to a range of 
trauma-focused 
interventions, evidence-
based non-trauma-focused 
psychological interventions 
(such as stress inoculation 
training) should be 
considered 
Not applicable 
Insufficient 
Recommendation  
• Relaxation  
• Seeking Safety  
 
• Brief Eclectic 
Psychotherapy 
• Dialogical Exposure 
Therapy 
• Emotional freedom 
techniques 
• Interpersonal 
psychotherapy 
Not applicable  • Acceptance and 
Commitment Therapy 
• Dialectical Behavior 
Therapy 
• Seeking Safety 
• Skills Training in Affect 
and Interpersonal 
Regulation 
• Supportive counselling 
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• Observed and 
experimental integration 
• Psychodynamic 
psychotherapy 
• Psychoeducation 
• Relaxation training 
• REM desensitization 
• Supportive counselling 
Emerging 
Recommendation 
Not applicable • Single session cognitive 
behavioral therapy   
• Reconsolidation of 
traumatic memories 
• Virtual reality therapy 
• Written Exposure Therapy 
Not applicable Not applicable Not applicable 
Note. In order to make comparisons across the recommendations, the authors created their own strength of recommendation categories. Only rows for which there were 
recommendations were included in the table.  
Note. APA = American Psychological Association; ISTSS = International Society for Traumatic Stress Studies; NICE = National Institute for Health and Care Excellence; 
VA/DoD = Department of Veterans Affairs and Department of Defense. 
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Table 7c 
 
Pharmacotherapy Recommendations for PTSD 
 
 APA, 2017 ISTSS, 2018 NICE, 2018 Phoenix, 2013 VA/DoD, 2018 
Strong 
Recommendation  
For 
    • Fluoxetine 
• Paroxetine 
• Sertraline 
• Venlafaxine  
Moderate 
Recommendation 
For 
 
• Fluoxetine 
• Paroxetine 
• Sertraline 
• Venlafaxine 
 • Selective serotonin reuptake 
inhibitors (such as sertraline) 
• Venlafaxine  
• Antipsychotics, such as 
risperidone (in addition to 
psychological therapies and 
only if they have disabling 
symptoms and behaviors and 
symptoms have not responded 
to other drug or psychological 
treatments) 
  
 
• Nefazodone 
• Imipramine 
• Phenelzine  
 
Low Recommendation 
For 
Not applicable • Fluoxetine 
• Paroxetine 
• Sertraline 
• Venlafaxine  
Not applicable Selective serotonin reuptake 
inhibitors  
Not applicable 
Emerging 
Recommendation 
Not applicable • Quetiapine Not applicable Not applicable Not applicable 
Moderate 
Recommendation 
Against 
 
 
  Not applicable • Amitriptyline 
• Citalopram 
• Lamotrigine 
• Olanzapine 
• Other atypical 
antipsychotics (except for 
risperidone, which is a Strong 
Against) 
• Prazosin (for the global 
symptoms of PTSD)  
• Quetiapine 
• Topiramate  
 
Strongest 
Recommendation 
Against 
   Not applicable • Benzodiazepines 
• D-cycloserine 
• Divalproex 
• Guanfacine 
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• Hydrocortisone 
• Ketamine 
• Risperidone 
• Tiagabine 
Insufficient 
Recommendation 
• Risperidone  
• Topiramate 
 
• Amitriptyline 
• Brofaromine 
• Divalproex 
• Ganaxolone 
• Imipramine 
• Ketamine 
• Lamotrigine 
• Mirtazapine 
• Neurokinin-1 Antagonist 
• Olanzapine 
• Phenelzine  
• Tiagabine  
• Topiramate 
 
Not applicable  • Bupropion 
• Buspirone 
• Cyproheptadine 
• Desipramine 
• Desvenlafaxine 
• Doxepin 
• D-serine 
• Duloxetine 
• Escitalopram 
• Eszopiclone 
• Fluvoxamine 
• Hydroxyzine 
• Levomilnacipran 
• Mirtazapine 
• Nortriptyline 
• Razodone 
• Vilazodone 
• Vortioxetine 
• Zaleplon 
• Zolpidem 
 
Note. In order to make comparisons across the recommendations, the authors created their own strength of recommendation categories. Only rows for which there were 
recommendations were included in the table. 
Note. APA = American Psychological Association; ISTSS = International Society for Traumatic Stress Studies; NICE = National Institute for Health and Care Excellence; 
VA/DoD = Department of Veterans Affairs and Department of Defense. 
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Table 7d  
 
Other Recommendations for PTSD 
 
 APA, 2017 ISTSS, 2018 NICE, 2018 Phoenix, 2013 VA/DoD, 2018 
Group Not addressed 
 
• Moderate recommendation: 
Group cognitive behavioral 
therapy with a trauma focus  
• Emerging Recommendation: 
Combined group plus individual 
with a trauma focus  
• Insufficient recommendation:  
Group interpersonal therapy, 
group stabilizing treatment, 
group supportive counselling  
 Low Recommendation: Group 
cognitive behavioral therapy 
(trauma-focused or non-trauma-
focused) may be provided as 
adjunctive to, but not be 
considered an alternative to, 
individual trauma-focused 
therapy  
• Moderate recommendation: 
Group therapy over no 
treatment  
• Insufficient recommendation: 
There is insufficient evidence to 
recommend using one type of 
group therapy over any other  
Couples  Not addressed Emerging Recommendation: 
Couples CBT with a trauma 
focus  
Insufficient recommendation: 
Cognitive-behavioral 
conjoint therapy  
Not addressed Insufficient recommendation: 
Trauma-focused or non-trauma-
focused couples therapy  
Internet-based Not addressed Moderate recommendation: 
Guided internet-based trauma-
focused CBT  
Moderate recommendation: 
Guided internet-based trauma-
focused CBT  
Low Recommendation: 
Internet-based trauma-focused 
CBT as an alternative to 
treatment  
Moderate recommendation: 
Guided internet-based CBT as 
an alternative to no treatment  
Complementary 
and Integrative 
Health 
Not addressed • Emerging Recommendation: 
Acupuncture, neurofeedback, 
somatic experiencing, 
Saikokeishikankyoto, somatic 
experiencing, and yoga  
• Insufficient recommendation: 
Attentional bias modification, 
electroacupuncture, 
hypnotherapy, Mantram 
Repetition, group Mindfulness 
Based Stress Reduction, group 
music therapy, nature adventure 
therapy and physical exercise  
Insufficient recommendation: 
Acupuncture, arts therapies, 
biofeedback, exercise, 
meditation or mindfulness-
based stress reduction (MBSR), 
neurofeedback and yoga. 
 
Very Low Recommendation: 
Acupuncture for people who 
have not responded to trauma-
focused psychological therapy 
or pharmacotherapy  
Insufficient recommendation: 
Acupuncture or any 
complementary and integrative 
health practice, such as 
meditation (including 
mindfulness), yoga, and 
mantram meditation  
Non-
Pharmacologic 
Biological 
Not addressed Emerging Recommendation: 
Transcranial Magnetic 
Stimulation  
Insufficient recommendation: 
Repetitive transcranial magnetic 
stimulation   
 Insufficient recommendation: 
Repetitive transcranial magnetic 
stimulation, electroconvulsive 
therapy, hyperbaric oxygen 
therapy, stellate ganglion block, 
and vagal nerve stimulation.  
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Note. In order to make comparisons across the recommendations, the authors created their own strength of recommendation categories. 
Note. APA = American Psychological Association; ISTSS = International Society for Traumatic Stress Studies; NICE = National Institute for Health and Care Excellence; 
VA/DoD = Department of Veterans Affairs and Department of Defense. 
 
 
